Skip to main content
SpringerLink
Log in

Pharmacological Properties of Parenteral Cephalosporins

Rationale for Ambulatory Use

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Parenteral cephalosporins are among the most frequently used antibiotics in hospital therapy. They are characterised by an extended spectrum of activity against Gram-positive and Gram-negative bacteria, and some also have good activity against anaerobes. They kill proliferating bacterial cells rapidly, and generally show only a low tendency to select resistant mutants. However, there are cephalosporin compounds which induce cephalosporinases very rapidly in certain microorganisms. Together with other β-lactam antibiotics, parenteral cephalosporins interfere with bacterial cell wall synthesis by inhibiting peptidoglycan cross-linkage. Because of this specific target, they are nontoxic to mammalian cells, and have a very favourable adverse effect profile. The chemical stability of parenteral cephalosporins in aqueous solution is good. After intravenous injection, high concentrations of these agents are achieved in serum and tissue. Most cephalosporins are eliminated unchanged via the kidney, with a half-life of 1 to 2 hours. But there are also derivatives with a serum half-life of more than 2 and up to 8 hours, allowing 12- or 24-hour dosage intervals. Because of their reliable efficacy and low risk of adverse effects, the parenteral cephalosporins offer a high degree of tolerability even in the setting of outpatient antibiotic therapy. In particular, the derivatives of the third generation are characterised by unique pharmacological properties.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Williams JD. Classification of cephalosporins. Drugs 1987; 34 Suppl. 2: 15–22

    Article  PubMed  CAS  Google Scholar 

  2. Bryskier A, Aszodi J, Chantot JF. Parenteral cephalosporin classification. Exp Opin Invest Drugs 1994;3: 145–71

    Article  CAS  Google Scholar 

  3. Klein NC, Cunha BA. The selection and use of cephalosporins: a review. Adv Ther 1995; 12: 83–101

    PubMed  CAS  Google Scholar 

  4. Simon C, Stille W. Cephalosporine. In: Simon C, Stille W, editors. Antibiotikatherapie in Klinik und Praxis. Stuttgart, New York: Schattauer, 1997: 69–112

    Google Scholar 

  5. Williams JD, Moosdeen F. In vitro antibacterial effects of cephalosporins. Drugs 1987; 34 Suppl. 2: 44–63

    Article  PubMed  CAS  Google Scholar 

  6. Bryan JP. Cephalosporins and carbapenems. Curr Opin Infect Dis 1991; 4: 727–41

    Article  Google Scholar 

  7. Neu HC. Structure-activity relationships: biological. In Page MI, editor. The chemistry of \-lactams. London: Blackie Academic & Professional, 1992: 103–28

    Google Scholar 

  8. Strehl E. Struktur-Wirkungsvergleiche bei parenteralen Cephalosporinen und Carbapenemen. Krankenhauspharmazie 1996; 17: 285–9

    Google Scholar 

  9. Adu A, Armour CL. Drug utilisation review (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423–39

    Article  PubMed  CAS  Google Scholar 

  10. Kaiman D, Barriere SL. Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins. Tex Heart Inst J 1990; 17: 203–15

    Google Scholar 

  11. Fekety FR. Safety of parenteral third-generation cephalosporins. Am J Med 1990; 88: 38–44

    Article  Google Scholar 

  12. Kayser FH. Basic aspects of antibiotic resistance in the multiresistant staphylococcus: an overview. Chemotherapy 1996; 42 Suppl. 2: 2–12

    Article  Google Scholar 

  13. Thompson JW, Jacobs RF. Adverse effects of newer cephalosporins. An update. Drug Saf 1993; 9: 132–42

    CAS  Google Scholar 

  14. Livermore DM. Mechanisms of resistance to cephalosporin antibiotics. Drugs 1987; 34 Suppl. 2: 64–88

    Article  PubMed  CAS  Google Scholar 

  15. Cunha BA. Third-generation cephalosporins: a review. Clin Ther 1992; 14: 616–52

    PubMed  CAS  Google Scholar 

  16. Klein N, Cunha BA. Third-generation cephalosporins. Med Clin North Am 1995; 79: 705–19

    PubMed  CAS  Google Scholar 

  17. Cherubin CE, Eng RHK, Norrby R, et al. Penetration of newer cephalosporins into cerebrospinal fluid. Rev Infect Dis 1989; 11: 526–48

    Article  PubMed  CAS  Google Scholar 

  18. Wise R. Tissue penetration of the fourth generation parenteral cephalosporins. J Chemother 1996; 8 Suppl. 2: 63–72

    PubMed  Google Scholar 

  19. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89–96

    Article  PubMed  CAS  Google Scholar 

  20. Outpatient parenteral antibiotic therapy. Management of serious infections. Part I: medical, socioeconomic, and legal issues. Symposium proceedings. Sonoma, California, Jan 26–27, 1993. Hosp Pract Off Ed 1993; 28 Suppl. 1: 5–64

  21. Outpatient parenteral antibiotic therapy. Management of serious infections. Part II: Amenable infections and models for delivery. Symposium proceedings. Sonoma, California, Jan 26–27, 1993. Hosp Pract Off Ed 1993; 28 Suppl. 2: 1–64

    Google Scholar 

  22. Benet LZ, Phie S, Schwartz JB. Design and optimization of dosage regimens: pharmacokinetic data. In: Goodman & Gilman, editors. The pharmacological basis of therapeutics. New York: McGraw-Hill, 1996: 1707–92

    Google Scholar 

  23. Stöckel K. Pharmakokinetik parenteraler Cephalosporine in Prüfphase III. Fortschr Antimicrob Antineopl Chemother 1982; 1: 105–13

    Google Scholar 

  24. Christ W. Pharmacological properties of cephalosporins. Infection 1991; 19 Suppl. 5: 244–52

    Article  Google Scholar 

  25. Brockmeier D, Dagrosa EE. Pharmacokinetic profile of cefodizime. Infection 1992; 20 Suppl. 1: S14–S17

    Article  PubMed  CAS  Google Scholar 

  26. Conte Jr JE. Pharmacokinetics of cefodizime in volunteers with normal or impaired renal function. J Clin Pharmacol 1994; 34: 1066–70

    PubMed  Google Scholar 

  27. Barriere SL, Hatheway GJ, Gambertoglio JG, et al. Pharmacokinetics of cefonicid, a new broad-spectrum cephalosporum. Antimicrob Agents Chemother 1982; 21(6): 935–8

    Article  PubMed  CAS  Google Scholar 

  28. Rockowitz J, Tunkel AR. Bacterial meningitis. Drugs 1995; 50: 838–53

    Article  PubMed  CAS  Google Scholar 

  29. Neu HC. Cephalosporins in the treatment of meningitis. Drags 1987; 34 Suppl. 2: 135–53

    Article  Google Scholar 

  30. Ter Braak EW, de Vries PJ, Bouter KP, et al. Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med 1990; 89: 58–66

    Article  PubMed  Google Scholar 

  31. Francioli P, Ruch W, Stamboulian D. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. Clin Infect Dis 1995; 21: 1406–10

    Article  PubMed  CAS  Google Scholar 

  32. Baskin MN, O'Rourke EJ, Fleisher GR. Outpatient treatment of febrile infants 28 to 89 days of age with intramuscular administration of ceftriaxone. J Pediatr 1992; 120: 22–7

    Article  PubMed  CAS  Google Scholar 

  33. Bergan T. Pharmacokinetic properties of the cephalosporins. Drugs 1987; 34 Suppl. 2: 89–104

    Article  PubMed  CAS  Google Scholar 

  34. Klepser ME, Marangos MN, Patel KB, et al. Clinical pharmacokinetics of newer cephalosporins. Clin Pharmacokinet 1995; 28: 361–84

    Article  PubMed  CAS  Google Scholar 

  35. Yuk-Choi JH, Nightingale CH, Williams Jr TW. Considerations in dosage selection for third generation cephalosporins. Clin Pharmacokinet 1992; 22: 132–43

    Article  PubMed  CAS  Google Scholar 

  36. Patel IH, Sugihara JG, Weinfeld RE, et al. Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment. Antimicrob Agents Chemother 1984; 25: 438–42

    Article  PubMed  CAS  Google Scholar 

  37. Ti TY, Fortin L, Kreeft JH, et al. Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis. Antimicrob Agents Chemother 1984; 25: 83–7

    Article  PubMed  CAS  Google Scholar 

  38. Cohen D, Appel GB, Scully B, et al. Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing haemodialysis. Antimicrob Agents Chemother 1984; 24: 529–32

    Article  Google Scholar 

  39. Neu HC. Third generation cephalosporins: safety profiles after 10 years of clinical use. J Clin Pharmacol 1990; 30: 396–403

    PubMed  CAS  Google Scholar 

  40. Kumana CR, Yuen KY Parenteral aminoglycoside therapy. Drags 1994; 47: 902–13

    Article  CAS  Google Scholar 

  41. Nathwani D. Outpatient treatment with teicoplanin. Chemotherapie J 1996; 5 Suppl. 1: 35–8

    Google Scholar 

  42. Marra F, Partovi N, Jewesson P. Aminoglycoside administration as a single daily dose. Drags 1996; 52: 344–70

    Article  CAS  Google Scholar 

  43. Rybak MJ, McGrath BJ. Combination antimicrobial therapy for bacterial infections. Drags 1996; 52: 390–405

    Article  CAS  Google Scholar 

  44. Mauceri AA, HIAT Study Group. Treatment of bone and joint infections utilizing a third-generation cephalosporin with an outpatient drag delivery device. Am J Med 1994; 97 Suppl. 2A: 14–22

    Article  PubMed  CAS  Google Scholar 

  45. Mustafa MM, Aquino VM, Pappo A, et al. A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. J Pediatr 1996; 128: 847–9

    Article  PubMed  CAS  Google Scholar 

  46. Poretz DM, HIAT Study Group. Treatment of skin and soft-tissue infections utilizing an outpatient parenteral drug delivery device: a multicenter trial. Am J Med 1994; 97 Suppl. 2A: 23–7

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Pharmacy, Hospital of the Albert-Ludwigs-University of Freiburg/Br., Freiburg, Germany

    Egid Strehl (Direktor Klinikumsapotheke) & Frieder Kees

Authors
  1. Egid Strehl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frieder Kees
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Strehl, E., Kees, F. Pharmacological Properties of Parenteral Cephalosporins. Drugs 59 (Suppl 3), 9–18 (2000). https://doi.org/10.2165/00003495-200059003-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200059003-00002

Keywords

Search

Navigation